You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Prediction and Measurement of the Carbon Build-Up in Film-Cooled Rocket Engines

    SBC: SIERRA ENGINEERING, INC.            Topic: AF15AT21

    ABSTRACT: Sierra Engineering Inc. (Sierra) believes that existing chemical kinetic models can be efficiently incorporated into commercial CFD codes to predict the mixing, pyrolysis, soot formation and carbon deposition within film cooled rocket engines. During this Phase I STTR effort we will demonstrate that this analysis capability is practical and that we can generate appropriate model validati ...

    STTR Phase I 2015 Department of DefenseAir Force
  2. Novel Silica-Based Organic Polymer for Ambient Ionization Mass Spectrometry

    SBC: Prosolia, Inc.            Topic: NIGMS

    DESCRIPTION provided by applicant Most samples of chemical interest are complex mixtures making the usual combination of chromatography with mass spectrometry MS a natural choice However the increased demand for chemical analysis by mass spectrometry in many areas of science makes it imperative to increase efficiency of analysis by minimizing sample workup and overall analysis time which ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Lowering the Cost of Imaging for Retinal Microvasculature in Diabetic Patients

    SBC: AEON IMAGING, LLC            Topic: W

    DESCRIPTION provided by applicant Recently we found extensive remodeling of the microvasculature of the retina occurring in some diabetic patients much earlier than expected This provides the potential for novel biomarkers However the equipment is too expensive for most clinics and small practices These early retinal microvascular changes cannot be seen with routine clinical examination o ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Discovery of Oligodendrocyte Stimulators

    SBC: Medosome Biotec, LLC            Topic: 101

    DESCRIPTION provided by applicant Up to of low birth weight preterm infants manifest some form of periventricular white matter injury PWMI making it the most common form of brain injury affecting premature infants In the US infants per year are born at risk for PWMI and about children per year will develop PWMI World wide infants will be born each year at ri ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne muscular dystrophy is caused by mutations in the dystrophin gene resulting in the loss of the dystrophin glycoprotein complex in skeletal muscle Loss of dystrophin results in reduced sarcolemmal integrity progressive muscle damage and compromised muscle function There is currently no cure and limited treatment options for DMD and all affected child ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. A new generation of targeted therapeutics for the treatment of cancer

    SBC: NERX BIOSCIENCES, INC.            Topic: NCI

    DESCRIPTION provided by applicant Development of novel lung cancer therapeutics targeting the DNA damage response Abstract Lung tissue is constantly exposed to a wide variety of inhaled chemical agents While the majority of these maybe innocuous those that damage DNA have severe consequences Thus the DNA damage response DDR and DNA repair in these tissues is extremely important The vast ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Diagnosing aggressive prostate cancer by spectroscopic photoacoustic tomography

    SBC: Vibronix, Inc.            Topic: 102

    DESCRIPTION provided by applicant Prostate cancer PCa is the No killer among male cancer patients The ultimate test is based on transrectal ultrasound guided needle biopsy and histological examination of fixed prostate tissues This conventional diagnostic procedure is invasive missing cases of cancer due to small sampling volume Moreover it leads to an overtreatment of patients du ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. A biochemical companion diagnostic platform to measure kinase inhibitor pharmacodynamics in leukemia

    SBC: MICROFLUIDIC INNOVATIONS, LLC            Topic: 102

    DESCRIPTION provided by applicant Kinase inhibitors created a new paradigm in chemotherapy and are a major focus of new oncology drug development The Bcr Abl inhibitor imatinib was a breakthrough drug for chronic myelogenous leukemia with overwhelming early results however at least of patients are either intolerant resistant or experience recurrence within years and individual respo ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Metal ion-functionalized soluble nanopolymers: A new analytical platform for plas

    SBC: Tymora Analytical Operations, LLC            Topic: 300

    DESCRIPTION provided by applicant Mass spectrometry based proteomics is an emerging technology that has seen possible applications everywhere The technique can potentially use one drop of our blood to reveal onset and progress of diseases Current Randamp D using plasma serum proteome sample sets however is severely limited by the high complexity and dynamic range of protein concentrations ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne Muscular Dystrophy DMD is a fatal muscle disease affecting in every male births DMD results from mutations in the gene encoding the dystrophin a kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and a transmembrane protein complex called the dystrophin associated glycoprotein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government